Literature DB >> 26331813

Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population.

Lan-Ying Gou1,2, Fei-Yu Niu1,2, Yi-Long Wu2, Wen-Zhao Zhong2.   

Abstract

Recently, non-smoking-related lung cancer was classified as an independent disease entity because it is different from tobacco-associated lung cancer. Non-smoking-related lung cancer occurs more often in women than men, and the predominant histological type is adenocarcinoma (ADC) rather than squamous cell carcinoma. Most of the driver gene alterations that have been identified in ADC in never-smokers include epidermal growth factor receptor mutations, KRAS mutations, echinoderm microtubule-associated protein like 4/anaplastic lymphoma kinase fusion, and ROS1 fusion, among others. Meanwhile, significant progress has been made in the treatment of ADC. However, in comparison with ADC, no such available molecular targets exist for smoking-associated lung cancer, for which treatment strategies are limited. Next-generation sequencing has been widely applied to the discovery of more genetic profiles of lung cancers. This review summarizes the differences between smoking-related and non-smoking-related lung cancer as follows: different somatic mutation burdens, C:G→A:T transversions, common and novel driver genes, and treatment strategies. Overall, smoking-related lung cancer is more complicated than non-smoking-related lung cancer. Furthermore, we review the prevalence of driver genes in smoking-associated and non-smoking-associated lung cancers in the Chinese population.
© 2015 American Cancer Society.

Entities:  

Keywords:  Chinese population; driver gene; lung cancer; mutation burden; next-generation sequencing (NGS); nonsmoker; smoker; treatment strategy

Mesh:

Substances:

Year:  2015        PMID: 26331813     DOI: 10.1002/cncr.29531

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  28 in total

1.  Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single nucleotide variants in cancer cells in lung adenocarcinoma.

Authors:  Shoko Nakasone; Sachiyo Mimaki; Tomohiro Ichikawa; Keiju Aokage; Tomohiro Miyoshi; Masato Sugano; Motohiro Kojima; Satoshi Fujii; Takeshi Kuwata; Atsushi Ochiai; Masahiro Tsuboi; Koichi Goto; Katsuya Tsuchihara; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-06       Impact factor: 4.553

Review 2.  Lung cancer in never smokers-the East Asian experience.

Authors:  Fei Zhou; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2018-08

3.  Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer.

Authors:  Jun Zhao; Jiagen Li; Ning Li; Shugeng Gao
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

4.  Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.

Authors:  Dan Sha; Zhaohui Jin; Jan Budczies; Klaus Kluck; Albrecht Stenzinger; Frank A Sinicrope
Journal:  Cancer Discov       Date:  2020-11-02       Impact factor: 38.272

5.  First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.

Authors:  Tianhong Li; Patricia LoRusso; Michael L Maitland; Sai-Hong Ignatius Ou; Erkut Bahceci; Howard A Ball; Jung Wook Park; Geoffrey Yuen; Anthony Tolcher
Journal:  J Hematol Oncol       Date:  2016-03-10       Impact factor: 17.388

6.  Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors.

Authors:  Shang-Gin Wu; Yih-Leong Chang; Chong-Jen Yu; Pan-Chyr Yang; Jin-Yuan Shih
Journal:  ERJ Open Res       Date:  2017-07-12

7.  Peritoneum as the sole distant metastatic site of lung adenosquamous cell carcinoma: a case report.

Authors:  Pan Yang; Wei-Liang Li; Jeff-X Zhou; Yu-Bo Yang; Xia-Xiang Jin
Journal:  J Med Case Rep       Date:  2017-09-27

8.  Former smokers with non-small-cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis.

Authors:  Shanbo Zheng; Rui Wang; Yang Zhang; Yunjian Pan; Chao Cheng; Difan Zheng; Yihua Sun; Haiquan Chen
Journal:  Cancer Med       Date:  2016-05-26       Impact factor: 4.452

9.  Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia.

Authors:  Luka Brcic; Marko Jakopovic; Marija Misic; Fran Seiwerth; Izidor Kern; Silvana Smojver-Jezek; Franz Quehenberger; Miroslav Samarzija; Sven Seiwerth
Journal:  Diagn Pathol       Date:  2016-09-21       Impact factor: 2.644

Review 10.  Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations.

Authors:  Jun Wang; Baocheng Wang; Huili Chu; Yunfeng Yao
Journal:  Onco Targets Ther       Date:  2016-06-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.